HROW:NSD-Harrow Health Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 45.33

Change

+1.76 (+4.04)%

Market Cap

USD 1.60B

Volume

0.37M

Analyst Target

USD 10.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.08 (+0.68%)

USD 13.28B
NBIX Neurocrine Biosciences Inc

-2.46 (-2.01%)

USD 12.34B
ITCI Intracellular Th

-0.41 (-0.55%)

USD 7.97B
LNTH Lantheus Holdings Inc

+2.60 (+2.46%)

USD 7.33B
ALKS Alkermes Plc

+0.09 (+0.32%)

USD 4.58B
ALVO Alvotech

+0.06 (+0.54%)

USD 3.32B
HCM HUTCHMED DRC

+0.02 (+0.12%)

USD 2.95B
AMPH Amphastar P

+1.14 (+2.34%)

USD 2.38B
KNSA Kiniksa Pharmaceuticals Ltd

-0.12 (-0.47%)

USD 1.80B
SUPN Supernus Pharmaceuticals Inc

+0.12 (+0.38%)

USD 1.71B

ETFs Containing HROW

JFWD Jacob Forward ETF 9.76 % 0.00 %

+0.03 (+0.25%)

USD 2.08M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 304.73% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 304.73% 97% N/A 99% N/A
Trailing 12 Months  
Capital Gain 220.35% 99% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 220.35% 99% N/A 98% N/A
Trailing 5 Years  
Capital Gain 677.53% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 677.53% 98% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 43.76% 83% B 88% B+
Dividend Return 43.76% 83% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.89% 36% F 24% F
Risk Adjusted Return 58.43% 92% A 83% B
Market Capitalization 1.60B 86% B+ 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector